Search This Blog

Saturday, January 15, 2022

What I tell my patients who feel let down by getting Omicron despite 3 vax shots

 Many people who are vaccinated, boosted and had COVID before are getting it again — and they are furious. They no longer believe the doctors or the president. Several of my patients have come to me (via televisit) feeling I let them down by pushing them to get the vaccine and then the booster only to find themselves sick with Omicron.

What can I tell them?

For one thing, I can reassure them that their shots weren’t wasted: They were far less likely to get very sick with COVID after receiving the vaccine and even less so with a recent booster

I can and do also tell them that though I wish they hadn’t gotten Omicron, they are now protected not only against another bout of Omicron but also against the more dangerous Delta. I can tell them what the Biden administration isn’t: All immunity, no matter how you get it, matters.

Experts have wondered if Omicron’s much-milder symptoms are the result of a naturally milder virus, patients with immunity through infection or vaccination or a combination of all three. Of course, there are person-to-person variations, depending on underlying disease and immune status, but most scientists agree: The more immunity of any kind to COVID, the better.


A South African study released Friday has cheering news: Researchers found about a quarter of Omicron’s reduced risk of hospitalization or death, compared with Delta, is the result of the variant’s traits, with the rest of the risk reduced mostly by immunity.

COVID vaccination card.
Experts have wondered if Omicron’s much-milder symptoms are the result of a naturally milder virus, patients with immunity through infection or vaccination or a combination of all three.
Getty Images

Not only that, but multiple studies have shown that the Omicron variant itself affects the upper airways far more than the lungs, even as it’s much more transmissible than any other variant. This is exactly what happened in the later stages of 1918 Spanish flu pandemic, according to John M. Barry, author of “The Great Influenza: The Epic Story of the Deadliest Plague in History,” who spoke to me about it on SiriusXM’s Doctor Radio this week.

There is no guarantee that the same will happen now, but it would behoove our public-health leaders to make the comparison, as opposed to the constant fearmongering.

The obsession with testing and isolation is counterproductive not only because we lack readily available home tests, but also because the virus is now almost everywhere, and isolating yourself if you aren’t sick does little to decrease the amount of virus circulating in the community.

One reason President Joe Biden’s poll numbers are dropping is most Americans recognize that he overpromised on the vaccine. Vaccines have two essential purposes: to prevent spread and to decrease severity. And though the mRNA vaccines clearly decrease severity of infection, especially with a recent booster, they clearly are doing little to prevent spread. This makes the mandate argument even more unconvincing — why mandate a vaccine that doesn’t prevent spread of the pathogen?

Dr. Kakoto Iwasaki, world-renowned Yale immunologist, told me that she is working on a vaccine to prevent infection altogether by blocking uptake in the nasal passages. Now this might be a vaccine worth mandating to certain groups in the name of public safety, but it’s several months away at a minimum.

In the meantime, all we have is the cruel rhetoric against the unvaccinated and the consequences of the overpromising of a life-saving vaccine by drug companies, the media and politicians.

And the public is left not believing in any of them — or, for that matter, in doctors like me, who have been on the front lines saving lives but then all too often inhale the dogma of reproach.

“May I never see in the patient anything but a fellow creature in pain. Grant me the strength, time and opportunity always to correct what I have acquired,” said the greatest physician-philosopher of them all, Maimonides. We can echo that sentiment by telling our patients what we still don’t know, rather than flogging them with what little we do.

Marc Siegel, M.D., is a clinical professor of medicine and medical director of Doctor Radio at NYU Langone Health and a Fox News medical analyst.

https://nypost.com/2022/01/14/what-i-tell-my-patients-who-feel-let-down-by-getting-omicron-despite-three-vax-shots/

NYC schools crippled by week-long data service systems outage

 A company that makes millions in New York City taxpayer funds providing software to manage student data has been out of service for a week, hampering schools and raising fears of a privacy breach.

Illuminate Education sells a system called Skedula for teachers and administrators to track student attendance, grades, special-ed plans, behavioral problems and family contact information. A related system, Pupil Path, lets students and parents log on for information.

When the systems went down last Saturday, Illuminate said it appeared to be “the result of an attempted security incident.” The company did not explain or return messages from The Post, but emailed principals Friday it is transferring the data to a “new secured environment.”

The city Department of Education gave no reason for the shutdown, but some experts suggest Illuminate may be a victim of ransomware, in which hackers freeze a system and demand payments to release it. Such attacks have crippled other education agencies.

Illuminate has raked in more than $16 million from DOE schools in the last three years, records show.

The company is also linked to a scandal under ex-Chancellor Richard Carranza, who hired a California friend, Abram Jimenez, with a financial stake in Illuminate. Jimenez abruptly quit his $205,000-a-year job when the conflict-of-interest was exposed.

Teachers say the outage has hampered their ability to keep track of kids exposed to COVID-19.

Under DOE policy, when a student tests positive, every classmate — often in in multiple classes — must be given rapid tests to take at home.

Because of the outage, “we had to manually figure out the kid’s schedule,” a Queens high-school teacher said “How many kids are falling through the cracks on getting the rapid tests?”

NYC Schools Chancellor Richard A. Carranza speaks about schools reporting in September, as Mayor Bill de Blasio looks on outside the Village Academy.
Illuminate Education is linked to a scandal from ex-NYC schools chancellor Richard Carranza, who worked under former Mayor Bill de Blasio.
Dennis A. Clark for NY Post

Grading is also impeded:  “I’m physically writing down their grades like it’s 2005 again,” the teacher said.

Leonie Haimson, an NYC co-chair of the national  Parent Coalition for Student Privacy said a breach  “would be terrible.”

“Teachers often use the system to record very sensitive information about a student’s emotional state or behavior, and to recommend counseling or other intervention services,” she said.

DOE spokesman Nathaniel Styer said, “We’re in close communication with Illuminate Education as they investigate and have been informed that so far there is no confirmation any of our schools’ information was accessed or taken.” He said schools record official attendance and grades in DOE-run systems that “were not impacted by this incident.” 

https://nypost.com/2022/01/15/nyc-schools-crippled-by-illuminate-educations-data-outage/

NYC schools to allow remote option as attendance plunges during COVID surge

 A remote option is coming back to city schools in response to plunging attendance amid a surge in COVID-19 cases.

Under a new Department of Education policy, students who don’t show up even though they are not sick or under quarantine won’t be marked absent if they meet with teachers on Zoom office hours and get class materials online.

Students can still be marked present, for instance, if they log onto Google Classroom to view PowerPoint presentations, subject notes and assignments. They can also communicate with teachers via email.

“We’re giving students permission to stay home as long as they are showing some level of participation online,” a Queens teacher told The Post.

“The city is making attendance rates go up.”

The change, quietly posted online Friday and first reported by Gothamist, came a day after Mayor Eric Adams revealed he was willing to negotiate a “temporary remote option” with the teachers’ union. Schools Chancellor David Banks, speaking to a parents’ council the day before, cited “political pressure” among concerns.

After the holiday break on Jan. 3, attendance in DOE schools sunk to 67 percent. On Friday, the attendance was 75 percent. With an enrollment of 938,000 students, that means 234,500 kids missed classes. 

empty classroom with textbooks on desks
The move back to allow a remote learning option comes amid plummeting attendance numbers in city schools.
Getty Images


In an email to principals last week, First Deputy Chancellor Dan Weisberg said schools “cannot be required” to give online instruction or office hours to students absent for “non-COVID reasons” or if a family is keeping a student home and is requesting assignments.

Meanwhile, the cases of COVID-19, fueled by the highly contagious Omicron variant, have steadily mounted. On Friday alone, the DOE reported 4,536 students and 616 staffers with new infections, bringing the total since classes started in September to 143,647.

“However, if staff are willing and their supervisor approves,” they can do so “and be compensated accordingly,” Weisberg wrote.     

Schools can now mark students present using the reason code “65,” which can mean either present in-person — or absent from the classroom but learning remotely.

Kindergarten students wear their masks and are separated by plexiglass during a math lesson at the Milton Elementary School.
The DOE policy would allow students to meet with teachers virtually to get their schoolwork.
AP / Mary Altaffer

Mark Cannizzaro, president of the city principals’ union, said Saturday on the WBAI radio show “Talk out of School” that previously some students who didn’t  show up were logging on to learn or get work, but “there  was no way to mark them present.”

It’s unclear if the DOE will release data on students marked present remotely, as opposed to in-person.

DOE spokesman Nathaniel Styer said the city still considers schools “the safest places for young people to be,” but is trying to be the most flexible in providing an education to every student.” 

https://nypost.com/2022/01/15/nyc-schools-allow-remote-option-to-boost-attendance/

SPAC First Digital Health Acquisition files for $175M IPO, targeting healthcare tech

 First Digital Health Acquisition, a blank check company targeting healthcare technology, filed on Friday with the SEC to raise up to $175 million in an initial public offering.


The company plans to raise $175 million by offering 17.5 million units at $10. Each unit consists of one share of common stock and one-half of a warrant, exercisable at $11.50. At the proposed deal size, First Digital Health Acquisition would command a market value of $219 million. 

First Digital Health Acquisition is led by Chairman Charles Martin, the founder and Chairman of Martin Ventures; Co-CEO and Director Justin Dearborn, the CEO of PatientBond; and Co-CEO and Director Jonathan Phillips, Managing Director and Head of Private Equity for FTCP. The company seeks to leverage management's experience and target the healthcare industry, specifically in the healthcare technology, healthcare technology-enabled services, or digital health subsectors. 

The Nashville, TN-based company was founded in 2021 and plans to list on the NYSE under the symbol FDHAU. First Digital Health Acquisition filed confidentially on June 22, 2021. William Blair is the sole bookrunner on the deal.

Medical device company Spinal Elements officially withdraws $108 million IPO

 Spinal Elements Holdings, which develops medical devices for minimally invasive spinal surgery procedures, withdrew its plans for an initial public offering on Friday. It had filed to raise $108 million by offering 7.7 million shares at a price range of $13 to $15, but postponed in October 2021.


The Carlsbad, CA-based company was founded in 2003 and booked $93 million in sales for the 12 months ended June 30, 2020. It had planned to list on the Nasdaq under the symbol SPEL. Credit Suisse, Baird, Stifel, Truist Securities, and BTIG were set to be the joint bookrunners on the deal.

Cancer biotech Arcellx files for a $100 million IPO

 Arcellx, a Phase 1 biotech developing immunotherapies for patients with cancer and other incurable diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.


Arcellx's lead ddCAR candidate, CART-ddBCMA, is in Phase 1 development for the treatment of relapsed or refractory (r/r) multiple myeloma (MM). The company believes preliminary results from the trial demonstrate that D-Domains can potentially provide meaningful clinical benefits. Arcellx plans to initiate a Phase 2 pivotal trial of CART-ddBCMA for treatment of r/r MM in late 2022, as well as pursue development of the candidate in earlier lines of therapy.

The Gaithersburg, MD-based company was founded in 2014 and plans to list on the Nasdaq under the symbol ACLX. Arcellx filed confidentially on May 1, 2020. BofA Securities, SVB Leerink, Barclays, and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.

Gilead withdraws use of Zydelig to treat two types of cancer

 Gilead Sciences Inc on Friday notified the U.S. health regulator of its decision to voluntarily withdraw the use of its drug Zydelig for two types of cancer - follicular lymphoma and small lymphocytic leukemia.

The U.S. Food and Drug Administration gave the drug an accelerated approval https://www.reuters.com/article/us-cancer-drugs-approval-idUSKBN0FS1ST20140723 in 2014 to treat relapsed follicular B-cell non-Hodgkin lymphoma and relapsed small lymphocytic leukemia along with relapsed chronic lymphocytic leukemia (CLL).

The approval, however, came with a boxed warning highlighting the risk of serious and potentially fatal toxicities.

Two years later, a regulatory review https://www.reuters.com/article/gilead-sciences-cancer-europe-idUSL5N16J4ZV of the drug's safety was launched by the European and U.S. regulators due to concerns over serious adverse events, including deaths.

Gilead said Zydelig will continue to be sold in the U.S. market for treating CLL. It will be available to treat CLL and FL in the European Union, the UK, Canada, Australia, New Zealand and Switzerland

https://www.marketscreener.com/quote/stock/GILEAD-SCIENCES-INC-4876/news/Gilead-withdraws-use-of-Zydelig-to-treat-two-types-of-cancer-37552783/